A Phase 2, Multi-center, Multi-arm, Randomized, Placebo-controlled, Double-blind, Adaptive Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Potential Pharmacotherapeutic Interventions in Active-Duty Service Members and Veterans With PTSD

This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for PTSD utilizing an adaptive platform trial design.
Intervention B - Vilazodone will assess the safety and efficacy of vilzodone in participants with PTSD.
Please see NCT05422612 for information on the S-21-02 Master Protocol.

开始日期2025-11-01

申办/合作机构

Cambridge Cognition Ltd.

[+5]

NCT05422612

/ Recruiting临床2期IIT

This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for PTSD utilizing an adaptive platform trial design. Participants are randomized among the multiple cohorts in the study and the resulting randomization enables sharing/pooling of control participants, where all interventions may be compared to a common control (placebo). This master protocol describes the default procedures and analyses for all cohorts; treatment-specific procedures will be described in the Master Protocol cohort-specific appendices. Individual cohorts may have additional eligibility requirements, safety and efficacy procedures, or endpoints, which will be described in corresponding intervention-specific clinicaltrials.gov records.

开始日期2023-11-02

申办/合作机构

Cambridge Cognition Ltd.

[+5]

CTRI/2022/07/043818

/ CompletedN/AIIT

Efficacy and safety of Vilazodone versus Escitalopram versus Vortioxetine as Antidepressant in patients with major Depressive Disorder : An open-labeled randomizes study in a Tertiary care hospital

开始日期2022-07-11

申办/合作机构-

100 项与盐酸维拉佐酮相关的临床结果

登录后查看更多信息

100 项与盐酸维拉佐酮相关的转化医学

登录后查看更多信息

100 项与盐酸维拉佐酮相关的专利（医药）

登录后查看更多信息

367

项与盐酸维拉佐酮相关的文献（医药）

2026-03-01·Journal of hand surgery global online

Antidepressant Use and Risk of Reoperation After Distal Radius Open Reduction and Internal Fixation: A Propensity Score-Matched Cohort Study

Article

作者: Ketonis, Constantinos ; Dussik, Christopher ; Kurbanov, Firdavs ; Rouege, Zion ; Wilbur, Danielle ; Phan, Amy

Purpose:

Antidepressant use is common and has been linked to impaired bone remodeling, but its effect on fracture healing after fixation remains unclear. The purpose of this study was to examine whether selective serotonin reuptake inhibitors (SSRIs) and, separately, agents that modulate serotonergic signaling but are not SSRIs (non-SSRI serotonergic antidepressants) were associated with unplanned return to the operating room (RTOR) after open reduction and internal fixation (ORIF) of distal radius fractures.

Methods:

We performed a retrospective, propensity score-matched cohort study using TriNetX, a global federated research network that aggregates deidentified electronic health record data from large health care organizations. Adults who underwent surgery within 14 days of distal radius fracture diagnosis were included and the ORIF date served as the index. Two mutually exclusive exposure comparisons were analyzed: SSRI users versus nonusers and non-SSRI serotonergic users (serotonin-norepinephrine reuptake inhibitors), tricyclic antidepressants, serotonergic monoamine oxidase inhibitors, vortioxetine, or vilazodone versus nonusers, defined by ≥2 prescriptions in the 180 days preindex. Cohorts were balanced using 1:1 greedy nearest-neighbor propensity-score matching (caliper 0.10). The primary outcome was unplanned RTOR 30-365 days postindex, defined as nonunion repair or repeat fixation. We estimated absolute risk differences, risk ratios (RRs), and Cox hazard ratios (HRs) with 95% confidence intervals (CIs).

Results:

After matching, 2,657 SSRI users and 2,197 non-SSRI serotonergic users were compared with equal numbers of nonusers. Unplanned RTOR occurred in 47 (1.8%) SSRI users versus 20 (0.8%) nonusers (ARD 1.0%, RR 2.35, HR 2.25; 95% CI 1.33-3.79). Non-SSRI serotonergic users had 52 events (2.4%) versus 14 (0.6%) in nonusers (ARD 1.7%, RR 3.71, HR 3.62; 95% CI 2.01-6.54). Findings were consistent across absolute risk comparisons and time-to-event analyses.

Conclusions:

Preoperative antidepressant exposure to SSRIs or non-SSRI serotonergic agents was associated with a small but clinically relevant increase in unplanned reoperation after distal radius ORIF.

Type of study/level of evidence:

Prognostic III.

2026-02-01·ANTIVIRAL RESEARCH

Onvansertib and vilazodone inhibit SARS-CoV-2 replication via suppression of METTL3 RNA-m6A enzymatic activity

Article

作者: Xiong, Si-Dong ; Li, Xi-Ya ; Zheng, Yong-Tang ; Yang, Wen-Lan ; Luo, Rong-Hua ; Wang, Zi-Ling ; Zhang, Lu-Xi ; Zhang, Ting ; Zheng, Hong-Yi

The continuous emergence of new SARS-CoV-2 variants limits the effectiveness of current vaccines and monoclonal antibodies, highlighting the urgent need for complementary antiviral strategies. Targeting host proteins that are exploited by the virus represents a promising approach to achieve broad-spectrum inhibition. Given the recently established proviral role of METTL3-dependent RNA m⁶A modification in SARS-CoV-2 replication, we conducted a structure-based virtual screening to repurpose compounds with acceptable safety profiles. Subsequent biochemical validation identified onvansertib and vilazodone as direct METTL3 binders and potent inhibitors of its methyltransferase activity. Notably, both compounds effectively suppressed the replication of ancestral SARS-CoV-2 and Omicron BA.2 variant in vitro. Mechanistically, each compound potentially enhanced the innate antiviral response of the host and repressed the expression of viral entry-associated host factors during infection; this observation is consistent with the established proviral role of METTL3. In summary, these findings not only substantiate METTL3 as a viable antiviral target but also lay the foundation for further research on the therapeutic potential of onvansertib and vilazodone against COVID-19.

2025-11-27·JOURNAL OF MEDICINAL CHEMISTRY

FDA Drug Repurposing Uncovers Modulators of Dopamine D ₂ Receptor Localization via Disruption of the NCS-1 Interaction

Article

作者: Sánchez-Barrena, María José ; Argerich, Josep ; Rodríguez-Martín, Eulalia ; Miró-Rodríguez, Celia ; Muñoz-Reyes, Daniel ; Campillo, Nuria E. ; Arroyo-Urea, Sandra ; Requena, Carlos ; Aguado, Lorena ; García-Nafría, Javier ; Ulzurrun, Eugenia ; Sánchez-Yepes, Sonia ; Mansilla, Alicia ; Pérez-Suárez, Sara

Dopamine D₂ receptor (D₂R) regulates key aspects of motor control, cognition, and reward. Its function depends not only on ligand binding and signaling efficacy but also on the dynamic control of receptor localization at the cell surface. Neuronal calcium sensor 1 (NCS-1) interacts with D₂R in a Ca²⁺-dependent manner. Using in vitro and cellular assays, we found that NCS-1 promotes D₂R trafficking to the plasma membrane through active exocytosis while preserving canonical receptor pharmacology. A screen of FDA-approved drugs identified protein-protein interaction (PPI) modulators targeting the NCS-1/D₂R interface. Azilsartan medoxomil, atorvastatin, and vilazodone disrupt this interaction, reducing D₂R surface expression. Structural studies revealed that these compounds target NCS-1, overlap the D₂R binding site, and perturb the dynamics of the regulatory helix H10. These findings reveal an unexploited intracellular mechanism to modulate D₂R function via PPI modulation, offering a novel strategy to fine-tune dopaminergic tone beyond receptor blockade or direct agonism.

项与盐酸维拉佐酮相关的新闻（医药）

2026-02-03

·三眼观

等药不再熬十年！AI正在“算”出救命新药，这些突破太震撼

你有没有见过这样的无奈？一位阿尔茨海默症患者的家属，每天陪着记忆逐渐消退的亲人。他们盼着能有一款新药，哪怕只是延缓病情也好。可医生往往只能遗憾地说：“再等等。” 这一等，可能就是十年，甚至更久。很多人，终究没能等到希望。为什么新药要等十年？救命特效药，为啥要以“十年”为单位等待？不是药企不愿加速，而是传统药物研发，实在太难了。这就像在茫茫宇宙里，用最原始的望远镜找一颗特定的星星。不仅要找对方向，还得反复试错，每一步都充满未知。一组权威数据，更能说明这份艰难：传统药物研发，平均周期10-12年。从最初找病因、到最终药物上市，要闯过临床前研究、临床试验等多道关卡。其中，仅临床前研究，就占总周期的40%以上。平均研发成本，高达26亿美元。更残酷的是，即便投入这么大，最终能成功上市的药物，不足10%。绝大多数候选药物，都会在某个环节失败，无数患者的等待，最终落空。转机：AI开始“算”新药现在，一股新浪潮正在改变这一切——让AI去“算”出新药。 2026年初的JPM全球健康大会（全球医疗健康领域的“风向标”）上，AI制药从往年的边缘话题，直接成了全场焦点。礼来与英伟达豪掷10亿美元，共建AI药物实验室；赛诺菲更是拿出43亿美元，押注中国AI制药平台。这些重磅合作，正在改写全球药物研发的格局。解读：AI怎么“算”新药？可能有人会问：AI既不会做实验，也不会拿试管，怎么帮着研发新药？其实很简单。AI就像一位“超级研发大脑”，靠海量算力和智能算法，把传统研发的“盲目试错”，变成了“精准导航”。每一步，都快到超出想象。它的核心操作，主要分两步：第一步：快速锁定“疾病元凶”——靶点先搞懂一个关键概念：靶点。靶点，就是导致疾病的关键分子。比如，导致阿尔茨海默症的β淀粉样蛋白、引发癌症的突变基因，都是靶点。找到靶点，就相当于找到了治病的“突破口”。传统方法验证一个靶点是否有效，往往需要2-3年。而AI不一样，它能整合基因组学、蛋白质组学等多类数据，快速构建分析模型。最快3个月，就能完成传统2年的工作量。举个例子：在抗抑郁药维拉佐酮的分析中，AI不仅精准命中了所有已知靶点，还发现了3个未被记录的新靶点。后续实验证明，这些新靶点全部有效。第二步：高效筛选“治病钥匙”——药物分子找到靶点后，下一步就是找“钥匙”——能精准结合靶点、发挥治疗作用的化合物。这就像从亿万把钥匙里，找唯一能开锁的那把。传统筛选靠人工实验，周期要6-12个月，还得浪费大量试剂和时间。 AI则能在数字世界里，模拟分子结合的过程，直接预测化合物的活性和毒性。它能一次性排除90%以上的无效选项，效率大幅提升。英矽智能的案例很有说服力：其CDK20抑制剂项目，从识别靶点到找到活性化合物，仅用了30天。而传统方法，至少需要半年。 AI让新药更安全、更精准 AI给药物研发带来的，不只是“提速”，更重要的是“提质”——让整个过程更安全、更精准。 1. 优化临床试验，少走弯路临床试验，是新药上市前的“最后一道关卡”。传统临床试验，周期长达3-7年。还常因为患者招募不精准、数据处理繁琐，导致进度延误，甚至出现安全风险。 AI能通过自然语言处理技术，快速分析海量电子病历和医疗数据，精准匹配符合试验条件的患者。药明生物的案例很典型：在某自身免疫病药物的III期试验中，用AI筛选患者。最终，入组时间缩短45%，节省了3000万美元成本，患者有效率还提升了28%。这个案例，还被欧洲肿瘤内科学会评为“数字化试验标杆”。 2. 提前预测副作用，更安全传统研发中，很多药物在临床试验后期，甚至上市后，才发现严重副作用。最终只能被迫下架，既浪费研发资源，也让患者面临风险。 AI能通过算法，模拟药物在人体内的代谢过程，提前识别潜在毒性。这让药物研发，从“高风险赌局”，变成了“风险可控的科学”。比如Moderna的新冠疫苗研发：用AI预测病毒变异趋势，同步优化临床试验设计。仅用42天，就完成了候选疫苗设计，较传统流程缩短80%以上，还保障了疫苗的安全性和有效性。现状：AI制药，早已不是“概念” 现在的AI制药，早已不是“实验室里的概念”，而是正在规模化落地的现实。波士顿咨询数据显示： AI生成药物的I期临床试验成功率，达80%-90%，比传统方法提升60%；II期成功率达40%，处于历史最高水平。这对患者来说，意味着什么？意味着未来面对癌症、阿尔茨海默症、罕见病等难治疾病时，不用再经历“十年等待”的绝望。可能1-2年，就能等到新药上市。意味着新药研发成本大幅降低，未来“天价药”会越来越少，普通家庭也能吃得起救命药。你的期盼，可能改变未来想想那些被罕见病困扰的孩子，父母常年奔波在“找药”的路上，哪怕只有一丝希望，也不愿放弃。想想那些癌症患者，在化疗的痛苦中，盼着能有更有效的靶向药，延长生命的长度。想想那些阿尔茨海默症患者，他们逐渐忘记亲人、忘记世界，家人却只能眼睁睁看着，盼着能有药物留住他们的记忆。 AI制药的每一步突破，都是在为这些家庭，点亮希望之光。如果AI制药的时代全面到来，你最希望它优先攻克哪一类疾病？是夺走无数生命的癌症？是让亲人渐行渐远的阿尔茨海默症？是让孩子痛苦不堪的罕见遗传病？还是其他困扰你和家人的疾病？在评论区留下你的心愿，也许你的期盼，会随着AI技术的进步，变成现实。（本文部分信息、图片来自网络，且未能核实版权归属，不为商业用途。如有不当，敬请联系）关注我，看不一样的科技风景

2026-01-24

·分析测试百科网

Disitamab vedotin,维迪西妥单抗,2136633-23-1

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。Disitamab vedotinMCE 国际站：Disitamab vedotin品牌：MedChemExpress (MCE)货号：HY-P9985CAS：2136633-23-1中文名称：维迪西妥单抗Synonyms：维迪西妥单抗; RC48纯度：≥99.0%存储条件：-80°C,避光保存运输条件：使用干冰运输。产品活性：Disitamab vedotin (RC48) 是一种抗体-活性分子偶联物 (ADC)，包含抗人表皮生长因子受体2 (HER2) 的单克隆抗体，该单克隆抗体通过可降解连接子结合到细胞毒性剂 MMAE。Disitamab vedotin 增强抗肿瘤免疫。生物活性：Disitamab vedotin (RC48) 是一种抗体-药物偶联物 (ADC)，包含抗人表皮生长因子受体 2 (HER2) 的单克隆抗体，通过可裂解接头与细胞毒性药物偶联药剂单甲基 auristatin E (MMAE)。 Disitamab vedotin 增强抗肿瘤免疫力[1]。体外：抗体部分是针对HER2的人源化单克隆抗体，小分子毒素是单甲基auristatin E (MMAE)，一种合成抗肿瘤药物。蛋白酶可裂解接头将 MMAE 共价连接到抗体[2]。IC50 & Target：HER2热销产品：Insulin aspart | Phrixotoxin-1 (TFA) | Vilazodone (Hydrochloride) | INDY | Toltrazuril (sulfone) | Anagrelide (hydrochloride) | Cyclopentenyl uracil | Anethole trithione | Deoxyshikonin | O4I4Trending products：Recombinant Proteins | Natural Products | Fluorescent Dye | PROTAC | Oligonucleotides参考文献：[1]. Deeks ED. Disitamab Vedotin: First Approval. Drugs. 2021;81(16):1929-1935.[2]. Jiang J, et al. Preclinical safety profile of disitamab vedotin: a novel anti-HER2 antibody conjugated with MMAE. Toxicol Lett. 2020;324:30-37. [3]. Huang L, Wang R, Xie K, et al. A HER2 target antibody drug conjugate combined with anti-PD-(L)1 treatment eliminates hHER2+ tumors in hPD-1 transgenic mouse model and contributes immune memory formation. Breast Cancer Res Treat. 2022;191(1):51-61.品牌介绍:• MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；• 50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；• 产品种类涵盖各种重组蛋白，多肽，常用试剂盒，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；• 提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；• 设有专业的实验中心和严格的质控、验证体系；• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；• 产品的生物活性多经各国客户实验验证；• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；• 专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；• 与世界各大制药公司及知名科研机构建立了长期的合作。

抗体药物偶联物蛋白降解靶向嵌合体临床结果

2025-12-17

·河北医科大学药学院

张阳博士-副教授

张阳，博士，副教授、硕士研究生导师。研究方向：（1）AI驱动的药物靶点发现与机制研究：开发深度学习模型，结合分子动力学模拟技术，实现高精度靶点识别、蛋白结构与功能预测、药-靶结合机制探究等；（2）AI模型开发与智能化药物筛选：开发及优化基于序列的化合物和蛋白质相互作用预测模型，结合计算机辅助药物设计建立多标准药物筛选管线，通过活性验证及结构优化，助力基于靶点的药物发现；（3）生物医药大数据平台构建与应用：基于整合的生物大数据和深度学习模型，搭建生物医药数据云平台及开发在线筛选工具。主持河北省自然科学基金优秀青年基金项目、中央引导地方科技发展项目（自由探索类基础研究）、河北省高等学校科学技术青年拔尖研究项目和河北省高层次人才资助项目，参研河北省重点研发计划（生物医药创新专项）1项。近五年，参与发表SCI论文40余篇，其中以第一作者（共同第一作者）、通讯作者在Nucleic Acids Res.、Proc. Natl. Acad. Sci. U. S. A.、J. Chem. Inf. Model.、J. Pharm. Anal.等权威期刊上发表系列研究性论文，申请相关专利5项。代表性论文：(1) Mou M, Zhang Y, Qian Y, Zhou Z, Liao Y, Niu T, Hu W, Chen Y, Jiang R, Zhao H, Dai H *, Zhang Y *, Fu T *. druglikeFilter 1.0: An AI powered filter for collectively measuring the drug-likeness of compounds. J Pharm Anal. 2025; 101298.(2) Liu X #, Yang H #, Liu X #, Mou M, Liu J, Yan W, Niu T, Zhang Z, Shi H, Su X, Li X *, Zhang Y *, Jia Q *. Discovery of selective HDAC6 inhibitors driven by artificial intelligence and molecular dynamics simulation approaches. J Pharm Anal. 2025; 101338.(3) Zhang B, Shi X, Liu X, Liu Y, Li X, Wang Q, Huang D, Zhao W, Cui J, Cao Y, Chai X, Wang J, Zhang Y *, Wang X *, Jia Q *. Discovery of E0199: A novel compound targeting both peripheral NaV and KV7 channels to alleviate neuropathic pain. J Pharm Anal. 2025; 15: 101132.(4) Sun X #, Li H #, Chen Z #, Zhang Y #, Wei Z, Xu H, Liao Y, Jiang W, Ge Y, Zheng L, Li T, Wu Y, Luo M, Fang L, Dong X, Xiao M, Han L *, Jia Q *, Zhu F *. PDCdb: The biological activity and pharmaceutical information of peptide-drug conjugate (PDC). Nucleic Acids Res. 2025; 53: D1476–D1485.(5) Li F #, Mou M #, Li X, Xu W, Yin J *, Zhang Y *, Zhu F *. DrugMAP 2.0: Molecular atlas and pharma-information of all drugs. Nucleic Acids Res. 2025; 53: D1372–D1382.(6) Zhang Y #, Liu X #, Li F #, Yin J #, Yang H #, Li X, Liu X, Chai X, Niu T, Zeng S *, Jia Q *, Zhu F *. INTEDE 2.0: The metabolic roadmap of drugs. Nucleic Acids Res. 2024; 52: D1355–D1364.(7) Li X, Wang C, Chai X, Liu X, Qiao K, Fu Y, Jin Y, Jia Q *, Zhu F *, Zhang Y *. Discovery of potent selective HDAC6 inhibitors with 5-phenyl-1H-indole fragment: Virtual screening, rational design, and biological evaluation. J Chem Inf Model. 2024; 64(15): 6147–6161.(8) Fu T #, Li F #, Zhang Y #, Yin J #, Qiu W, Li X, Liu X, Xin W, Wang C, Yu L, Gao J, Zheng Q *, Zeng S *, Zhu F *. VARIDT 2.0: Structural variability of drug transporter. Nucleic Acids Res. 2022; 50: D1417–D1431.(9) Han Z, He D *, Zhang Y *. Genetic variant rs7820258 regulates the expression of indoleamine 2,3-dioxygenase 1 in brain regions. Proc Natl Acad Sci USA. 2020; 117(39): 24035–24036.(10) Zhang Y #, Zheng G #, Fu T, Hong J, Li F, Yao X, Xue W *, Zhu F *. The binding mode of vilazodone in the human serotonin transporter elucidated by ligand docking and molecular dynamics simulations. Phys Chem Chem Phys. 2020; 22(9): 5132–5144.专利申请：(1)张阳，李学东，贾庆忠，刘新岗，贺殿，朱峰；具有HDACs抑制活性的喹唑啉-4-胺衍生物及其制备方法与用途，2022-4-14，中国，ZL202210391023.4；(2)贾庆忠，李学东，刘新岗，张阳，王松松，剧苗苗，史晓兴，王香雨，祁金龙，张海林；一种具有NaV1.7钠离子通道靶向抑制作用的化合物及其药物组合物和用途，2022-12-13，中国，CN202211594787.X；(3)贾庆忠，张阳，朱峰，李学东，付炎，刘新岗，柴旭，刘鑫雨；具有HDAC6选择性抑制活性的5-芳基-1H-吲哚衍生物及其制备方法与用途，2024-8-02，中国，CN118420515A；(4)朱峰，牟敏杰，葛一超，牛天乐，张阳；一种基于对比学习和蛋白聚类策略的无配体靶标的配体预测方法，2025-03-04，中国，2025102490130；(5)朱峰，张阳，倪锋，牟敏杰，刘新岗；一种具有抗高表达AGTRAP乳腺癌活性的化合物及其应用，2025-02-27，中国，2025102241246。

100 项与盐酸维拉佐酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09699	盐酸维拉佐酮	N06AX24	DB06684

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
抑郁症	巴西	Libbs Farmacêutica Ltda.	2023-08-21
重度抑郁症	美国	AbbVie, Inc.	2011-01-21

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
广泛性焦虑障碍	临床3期	美国	Forest Laboratories LLC	2012-06-30
顺行性遗忘	临床2期	美国	Forest Laboratories LLC	2012-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01878292 (VLZ-MD-21, CTgov)	临床3期	重度抑郁症	529	Placebo (Placebo)	膚衊鏇簾廠鹹遞觸糧繭(夢蓋憲蓋簾醖襯鏇廠願) = 鹽艱構範壓鹹鹽製鏇鬱選願艱網齋願顧積壓鬱 (繭顧淵獵淵膚鬱壓夢壓, 0.921) 更多	-	2019-12-24
				Vilazodone (Vilazodone 15 mg)	膚衊鏇簾廠鹹遞觸糧繭(夢蓋憲蓋簾醖襯鏇廠願) = 觸鑰憲築糧糧醖夢鹹鑰選願艱網齋願顧積壓鬱 (繭顧淵獵淵膚鬱壓夢壓, 0.904) 更多
NCT01766401 (VLZ-MD-06, CTgov)	临床3期	广泛性焦虑障碍	402	Placebo (Placebo)	鬱觸膚艱窪鹹夢廠鬱範(窪鹽糧餘膚製範餘選糧) = 鹽積製鹹積夢鹽膚鏇憲築餘築襯範糧壓選積廠 (夢簾範餘積範衊糧糧衊, 7.37) 更多	-	2019-12-18
				Vilazadone (Vilazadone)	鬱觸膚艱窪鹹夢廠鬱範(窪鹽糧餘膚製範餘選糧) = 繭鏇鬱鑰襯膚襯鑰膚餘築餘築襯範糧壓選積廠 (夢簾範餘積範衊糧糧衊, 7.41) 更多
NCT01629966 (VLZ-MD-05, CTgov)	临床3期	广泛性焦虑障碍	680	Placebo (Placebo)	憲廠鹹願構醖衊選構廠(壓憲壓糧醖製廠築鹽廠) = 襯顧糧糧艱鹽積鹽觸窪觸範繭艱膚鹽範膚簾糧 (齋壓簾積簾觸鬱鹽糧壓, 7.93) 更多	-	2019-12-18
				Vilazodone (Vilazadone 20mg)	憲廠鹹願構醖衊選構廠(壓憲壓糧醖製廠築鹽廠) = 製糧淵膚壓鹹膚鹹選憲觸範繭艱膚鹽範膚簾糧 (齋壓簾積簾觸鬱鹽糧壓, 7.13) 更多
NCT01844115 (CTgov)	临床3期	广泛性焦虑障碍	415	Placebo (Placebo)	衊鬱製築鬱鹽願積衊餘(選積築襯鬱襯醖獵築範) = 製壓艱蓋憲積觸願窪廠簾遞淵遞願鬱範遞繭範 (範構衊築淵簾積衊襯鹹, 7.41) 更多	-	2019-12-18
				Vilazodone (Vilazodone)	衊鬱製築鬱鹽願積衊餘(選積築襯鬱襯醖獵築範) = 蓋蓋繭鏇遞鹹衊淵選繭簾遞淵遞願鬱範遞繭範 (範構衊築淵簾積衊襯鹹, 6.99) 更多
NCT02372799 (VLZ-MD-22, CTgov)	临床3期	重度抑郁症	473	Placebo (Placebo)	選鏇積窪膚鏇觸範膚繭(鬱艱窪願糧鹽淵糧窪夢) = 衊衊範範艱範廠鏇廠夢壓蓋膚製鹹膚簾糧襯憲 (網構網餘廠鹽鹹蓋廠鑰, 0.983) 更多	-	2019-10-01
				Vilazodone (Vilazodone)	選鏇積窪膚鏇觸範膚繭(鬱艱窪願糧鹽淵糧窪夢) = 糧鏇選襯網窪糧鬱淵獵壓蓋膚製鹹膚簾糧襯憲 (網構網餘廠鹽鹹蓋廠鑰, 0.977) 更多
NCT02436239 (VLZ-MD-23, CTgov)	临床3期	重度抑郁症	330	Placebo+Vilazodone (Placebo/Vilazodone)	網築觸顧蓋夢壓壓積衊 = 簾蓋鹹衊淵艱醖襯襯餘鬱窪夢製夢艱夢糧衊獵 (蓋壓網蓋鏇鹹鹽簾衊淵, 壓壓鏇觸夢鑰繭襯築範 ~ 願醖獵齋構憲醖糧願願) 更多	-	2019-09-11
				Vilazodone (Vilazodone/Vilazodone)	網築觸顧蓋夢壓壓積衊 = 糧壓築蓋憲構夢築鹹醖鬱窪夢製夢艱夢糧衊獵 (蓋壓網蓋鏇鹹鹽簾衊淵, 膚觸選鑰簾壓膚糧鬱積 ~ 鏇艱壓膚壓鏇醖醖淵製) 更多
NCT01828515 (CTgov)	临床2期	顺行性遗忘	24	Vilazodone+Hydrocortisone (Vilazodone and Hydrocortisone)	構願膚觸積範繭糧築壓(壓範蓋構夢顧淵糧餘憲) = 糧窪夢願獵廠膚構築鹹夢壓餘觸觸構鬱積衊蓋 (餘範築繭醖餘鹹網繭襯, 12.48) 更多	-	2018-07-05
				Placebo+Hydrocortisone (Placebo and Hydrocortisone)	構願膚觸積範繭糧築壓(壓範蓋構夢顧淵糧餘憲) = 壓膚遞選製鹽築顧齋窪夢壓餘觸觸構鬱積衊蓋 (餘範築繭醖餘鹹網繭襯, 7.98) 更多
NCT01999920 (CTgov)	临床4期	分离性焦虑	24	Vilazodone (Vilazodone)	顧壓醖範獵遞蓋醖築夢 = 積齋襯網簾顧襯築鏇齋觸膚膚壓繭願網構鬱鹹 (淵積醖壓鏇鑰廠範衊選, 範簾選衊積蓋願淵築憲 ~ 獵蓋壓壓製夢齋齋願鬱) 更多	-	2017-10-31
				Placebo (Placebo)	顧壓醖範獵遞蓋醖築夢 = 鏇顧繭鹹壓餘醖遞遞鏇觸膚膚壓繭願網構鬱鹹 (淵積醖壓鏇鑰廠範衊選, 齋繭襯蓋鹽窪窪範窪構 ~ 遞觸艱襯壓蓋衊獵壓簾) 更多
NCT00644358 (CTgov)	临床3期	重度抑郁症	616	vilazodone	鏇壓範衊選廠壓範繭齋 = 襯膚襯鬱鹽積鏇範繭醖鏇鬱醖鏇鹽齋蓋積鹹鹹 (衊夢鬱襯鏇願餘餘製淵, 艱觸鑰網遞壓淵鹽鏇鏇 ~ 鏇積憲觸獵鹹製築廠築) 更多	-	2017-09-25
NCT01715519 (Pubmed) 人工标引	临床4期	抑郁症 \| 创伤后应激障碍	59	vilazodone	願膚夢襯淵餘觸積簾鏇(選網壓醖遞鹽膚蓋夢鬱) = No significant differences were observed between the groups 淵夢膚齋積蓋廠餘衊艱 (鹹選製艱蓋壓夢鹽襯顧 ) 更多	不佳	2017-08-24
				Placebo